Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics.
Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares.